{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:29:00Z","timestamp":1793500140006,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jtct.2025.06.001","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T21:13:05Z","timestamp":1749157985000},"page":"863-873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Malignancies after Chimeric Antigen Receptor T Cell Therapy"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0189-8233","authenticated-orcid":false,"given":"Razan","family":"Mohty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2976-265X","authenticated-orcid":false,"given":"Amal","family":"Halwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-8404","authenticated-orcid":false,"given":"Hassan","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithun V.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4686-929X","authenticated-orcid":false,"given":"Hong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jtct.2025.06.001_bib0001","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtct.2025.06.001_bib0002","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.001_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.jtct.2025.06.001_bib0004","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.001_bib0005","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.001_bib0006","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.jtct.2025.06.001_bib0007","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jtct.2025.06.001_bib0008","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jtct.2025.06.001_bib0009","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.001_bib0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.001_bib0011","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.001_bib0012","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"10402","key":"10.1016\/j.jtct.2025.06.001_bib0013","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"10299","key":"10.1016\/j.jtct.2025.06.001_bib0014","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.jtct.2025.06.001_bib0015","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.001_bib0016","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.001_bib0017","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.jtct.2025.06.001_bib0018","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jtct.2025.06.001_bib0019","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.001_bib0020","doi-asserted-by":"crossref","first-page":"584_586","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"issue":"8010","key":"10.1016\/j.jtct.2025.06.001_bib0021","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/d41586-024-01215-0","article-title":"Do cutting-edge CAR-T-cell therapies cause cancer? What the data say","volume":"629","author":"Willyard","year":"2024","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.001_bib0022","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/jamaoncol.2023.7182","article-title":"Features and factors associated with myeloid neoplasms after chimeric antigen receptor T-cell therapy","volume":"10","author":"Gurney","year":"2024","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.001_bib0023","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41591-024-03478-6","article-title":"Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies","volume":"31","author":"Jadlowsky","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.001_bib0024","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/jamaoncol.2024.0662","article-title":"T-cell malignant neoplasms after chimeric antigen receptor t-cell therapy","volume":"10","author":"Storgard","year":"2024","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.001_bib0025","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.001_bib0026","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.001_bib0027","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-022-00707-4","article-title":"Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma","volume":"12","author":"Alkhateeb","year":"2022","journal-title":"Blood Cancer J"},{"issue":"15","key":"10.1016\/j.jtct.2025.06.001_bib0028","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","article-title":"Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy","volume":"5","author":"Miller","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.001_bib0029","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/2643-3230.BCD-21-0177","article-title":"Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma","volume":"3","author":"Saini","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.001_bib0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.jtct.2025.06.001_bib0031","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.jtct.2025.06.001_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.06.001_bib0033","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2023-179868","article-title":"Five year outcomes of patients with large B-cell lymphoma treated with standard-of-care axicabtagene ciloleucel: results from the US Lymphoma CAR-T Cell Consortium","volume":"142","author":"Spiegel","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.001_bib0034","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.001_bib0035","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/jamaoncol.2023.7182","article-title":"Features and factors associated with myeloid neoplasms after chimeric antigen receptor T-cell therapy","volume":"10","author":"Gurney","year":"2024","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.001_bib0036","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2025.06.001_bib0037","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/bloodadvances.2024012573","article-title":"Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy","volume":"8","author":"Melody","year":"2024","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.06.001_bib0038","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2024-203979","article-title":"Secondary hematologic malignancies in patients following chimeric antigen receptor T-cell therapy: aggregated clinical trial data from 1542 patients","volume":"144","author":"Cliff","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.001_bib0039","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41409-025-02541-1","article-title":"Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study","volume":"60","author":"Kharfan-Dabaja","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.06.001_bib0040","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41409-025-02529-x","article-title":"Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study","volume":"60","author":"Farina","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.06.001_bib0041","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/s41375-025-02605-7","article-title":"Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?","volume":"39","author":"Gazeau","year":"2025","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.001_bib0042","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood.2022015728","article-title":"Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs","volume":"140","author":"Steffin","year":"2022","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.jtct.2025.06.001_bib0043","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.001_bib0044","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.21971","article-title":"The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma","volume":"107","author":"Tward","year":"2006","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.jtct.2025.06.001_bib0045","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.001_bib0046","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Lymphoma Program Investigators at the University of Pennsylvania. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.001_bib0047","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2025.06.001_bib0048","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.jtct.2025.06.001_bib0049","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.001_bib0050","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1002\/hem3.54","article-title":"Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study","volume":"8","author":"Berning","year":"2024","journal-title":"Hemasphere"},{"issue":"15","key":"10.1016\/j.jtct.2025.06.001_bib0051","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","article-title":"Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy","volume":"3","author":"Shah","year":"2019","journal-title":"Blood Adv"},{"issue":"7709","key":"10.1016\/j.jtct.2025.06.001_bib0052","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.jtct.2025.06.001_bib0053","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.06.001_bib0054","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1182\/blood-2023-178806","article-title":"CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma","volume":"142","author":"Harrison","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.001_bib0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.06.001_bib0056","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood-2023-182817","article-title":"C-CAR039, a novel anti-CD20\/CD19 bi-specific CAR T-cell therapy shows deep and durable clinical benefits in patients with relapsed or refractory (r\/r) B-cell non-Hodgkin lymphoma (B-NHL) in long term follow up","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2025.06.001_bib0057","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/JOM.0000000000000879","article-title":"Risks associated with lentiviral vector exposures and prevention strategies","volume":"58","author":"Schlimgen","year":"2016","journal-title":"J Occup Environ Med"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.001_bib0058","doi-asserted-by":"crossref","DOI":"10.3390\/v13081528","article-title":"Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives","volume":"13","author":"Labbe","year":"2021","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.001_bib0059","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1371\/journal.ppat.0020060","article-title":"Retroviral DNA integration: viral and cellular determinants of target-site selection","volume":"2","author":"Lewinski","year":"2006","journal-title":"PLoS Pathog"},{"issue":"68","key":"10.1016\/j.jtct.2025.06.001_bib0060","doi-asserted-by":"crossref","DOI":"10.3791\/4327","article-title":"Generation of human induced pluripotent stem cells from peripheral blood using the STEMCCA lentiviral vector","author":"Sommer","year":"2012","journal-title":"J Vis Exp"},{"key":"10.1016\/j.jtct.2025.06.001_bib0061","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1038\/ncomms7381","article-title":"3D hotspots of recurrent retroviral insertions reveal long-range interactions with cancer genes","volume":"6","author":"Babaei","year":"2015","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.jtct.2025.06.001_bib0062","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.001_bib0063","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41591-024-03458-w","article-title":"T cell malignancies after CAR T cell therapy in the DESCAR-T registry","volume":"31","author":"Dulery","year":"2025","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.001_bib0064","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMoa2309728","article-title":"CAR+ T-cell lymphoma after cilta-cel therapy for relapsed or refractory myeloma","volume":"392","author":"Harrison","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.001_bib0066","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/oxfordjournals.annonc.a058589","article-title":"Etoposide and secondary haematological malignancies: coincidence or causality?","volume":"4","author":"Zulian","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2025.06.001_bib0067","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.euros.2024.02.013","article-title":"Risk of secondary malignancies after pelvic radiation: a population-based analysis","volume":"63","author":"McPartland","year":"2024","journal-title":"Eur Urol Open Sci"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.001_bib0068","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/ejh.14355","article-title":"Secondary malignancies after autologous stem cell transplantations in patients with malignant lymphoma and multiple myeloma","volume":"114","author":"Metzner","year":"2025","journal-title":"Eur J Haematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:30:47Z","timestamp":1793496647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725012187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":67,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2666636725012187"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.06.001","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignancies after Chimeric Antigen Receptor T Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}